In a recent presentation featured at the Midwest Business Group on Health's Mental Health Forum, an expert shed light on the evolving landscape shaped by the Mental Health Parity and Addiction Treatment Act.
In a recent presentation featured at the Midwest Business Group on Health's Mental Health Forum, an expert shed light on the evolving landscape shaped by the Mental Health Parity and Addiction Treatment Act. Margaret Faso, executive director of the American Health Policy Institute and senior director of Public Policy, HR Policy Association, discussed the intricacies of this legislation underscoring the newfound challenges confronting employers and health care providers.
"The Mental Health Parity and Addiction Act has been out since 2008. This has been law and requirement on employer plans so while DOL [Department of Labor] has been, I would say, understanding of the fact that these are increased requirements on employers and recognizing the fact that employers have been trying to improve their mental health benefits for their employees, there's also a tone of well, this isn't new, and you all should have been doing this from the very beginning," Faso said.
Among the focal points were heightened standards for outcomes data collection, the amplified stringency of audits, and the persistent hurdles posed by provider shortages and geographical limitations.
One of the discussion's central themes revolved around the act's potential ramifications on both employers and employees. Addressing this, Faso deliberated on the pros and cons of financial implications under the new regulatory framework. The critical importance of meticulously evaluating plan benefits and delegating responsibilities to third-party administrators to ensure compliance emerged as a recurrent motif throughout the discourse.
Action Items for Employers
Faso outlined several actionable steps that employers can take to navigate the complexities of the Mental Health Parity and Addiction Treatment Act effectively:
Key Insights and Challenges
Rule Changes for Employer Plans: With the enactment of this act, employers are mandated to ensure that mental health benefits are on par with medical benefits. This requirement places responsibility on employers to re-evaluate and potentially adjust their benefit structures to comply with the new regulations.
Employee Retirement Income Security Act (ERISA) of 1974 Regulations: Compliance with ERISA regulations presents a notable challenge for employers, particularly concerning the certification of comparative analyses for each NQTL. This necessitates a thorough understanding of ERISA requirements and diligent documentation of compliance efforts.
Mental Health and Substance Use Disorder Benefits: Employers express concerns about the equalization of prior authorization requirements for mental health and medical benefits. This raises questions about the impact on plan administration and the potential need for additional resources to manage the process effectively.
Health Care Plan Design and Compliance: Employers may face heightened costs and scrutiny for plan designs, especially concerning mental health and substance use disorder benefits. Balancing compliance with cost-effectiveness poses a significant challenge, requiring careful consideration of benefit design and allocation of resources.
Health Care Network Adequacy: Employers must address concerns regarding network adequacy and compliance with regulatory requirements. Delegating the analysis of third-party administrator contracts and ensuring robust networks are crucial steps to mitigate the risk of audits and maintain compliance with the Mental Health Parity and Addiction Treatment Act.
Overall, Faso acknowledged the complexity of the new requirements being placed on employer plans by the Mental Health Parity rule changes, including conducting detailed comparative analyses of benefits and collecting/evaluating outcomes data to ensure equal access to mental health services.
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
The Federal Trade Commission (FTC) issued letters to 10 companies to warn them that certain drug patents were improperly listed; the US Department of Agriculture (USDA) will begin testing ground beef for bird flu particles; rural Americans are more likely to die early from 1 of the 5 leading causes of death than those who live in urban areas.
Read More
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More